Additionally, analyses of publicly available datasets indicated that upregulation of CDC7 mediated by TP53/RB1 inactivation may occur beyond prostate and lung malignancies, and particularly in those tumors with a NE phenotype, suggesting that CDC7 inhibition may be an interesting therapeutic approach in combination with chemotherapeutic agents in many other tumor types, as we have demonstrated in another NE lung tumor type, LCNEC. The gene discussed is RB1; the disease is neoplasm.